BioMarin/BMRN

$74.03

-1.37%
-
1D1W1MYTD1YMAX

About BioMarin

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Ticker

BMRN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alexander Hardy

Employees

3,401

Headquarters

San rafael, United States

BioMarin Metrics

BasicAdvanced
$14B
Market cap
70.45
P/E ratio
$1.06
EPS
0.31
Beta
-
Dividend rate
$14B
0.30797
$99.56
$74.09
1.7M
2.744
1.698
11.699
21.443
73.13
3.09%
4.22%
3.54%
70.453
5.718
2.784
3.074
86.591
13.74%
180.33%
9.15%
232.51%

What the Analysts think about BioMarin

Analyst Ratings

Majority rating from 29 analysts.
Buy

Price Targets

Average projection from 25 analysts.
45.93% upside
High $140.00
Low $72.00
$74.03
Current price
$108.03
Average price target

BioMarin Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
13.65% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$649M
0.4%
Net income
$89M
336.45%
Profit margin
13.65%
334.71%

BioMarin Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 33.33%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.29
$0.21
$0.11
$0.46
-
Expected
$0.23
$0.23
$0.23
$0.35
$0.34
Surprise
24.53%
-10.29%
-52.91%
33.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for BioMarin stock?

BioMarin (BMRN) has a market cap of $14B as of May 30, 2024.

What is the P/E ratio for BioMarin stock?

The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 70.45 as of May 30, 2024.

Does BioMarin stock pay dividends?

No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next BioMarin dividend payment date?

BioMarin (BMRN) stock does not pay dividends to its shareholders.

What is the beta indicator for BioMarin?

BioMarin (BMRN) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the BioMarin stock price target?

The target price for BioMarin (BMRN) stock is $108.03, which is 45.93% above the current price of $74.03. This is an average based on projections from 25 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell BioMarin stock

Buy or sell BioMarin stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing